Shanghai-based biotechnology company developing circular RNA (circRNA) therapeutics
Shanghai-based biotechnology company developing circular RNA (circRNA) therapeutics. Its proprietary platform focuses on circRNA manufacturing and translation; the company reports multiple patent families and a pipeline of seven assets. Circular RNA is described as more stable and less immunogenic than linear RNA, with potential across broader therapeutic areas. No clinical results have been published to date.